{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T09:47:39Z","timestamp":1794995259739,"version":"4.9.1"},"reference-count":10,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Alzheimer\u2019s Disease"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:p>\n                    We evaluated whether apolipoprotein E (\n                    <jats:italic toggle=\"yes\">APOE<\/jats:italic>\n                    ) genotype-guided slow titration of monoclonal antibodies reduced amyloid-related imaging abnormalities (ARIA) in Alzheimer's disease. We retrospectively analyzed ARIA incidence in 25 patients on aducanumab and 19 patients on lecanemab on a genotype-informed protocol in a private practice setting. ARIA-E and ARIA-H each occurred in 4% of the aducanumab group and 5% of the lecanemab group. Plaque clearance was achieved in 50% of evaluable aducanumab patients and 26.3% of lecanemab patients. Compared to clinical trial ARIA rates, our results suggest that individualized, genotype-informed titration improves safety although plaque clearance rates were less robust.\n                  <\/jats:p>","DOI":"10.1177\/13872877251366657","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T14:22:01Z","timestamp":1755094921000},"page":"1400-1403","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Reducing ARIA risk in Alzheimer's disease: Real-world impact of\n                    <i>APOE<\/i>\n                    genotype-guided slow titration with aducanumab and lecanemab"],"prefix":"10.1177","volume":"107","author":[{"given":"Nicholas","family":"Mervosh","sequence":"first","affiliation":[{"name":"Park Avenue Neurology, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadir","family":"Bilici","sequence":"additional","affiliation":[{"name":"Park Avenue Neurology, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wisniewski","sequence":"additional","affiliation":[{"name":"New York University Grossman School of Medicine, Alzheimer's Disease Research Center, New York, NY, USA"},{"name":"Center for Cognitive Neurology, Department of Neurology, NYU Grossman School of Medicine, New York, NY, USA"},{"name":"Departments of Pathology and Psychiatry, NYU Grossman School of Medicine, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3367-9123","authenticated-orcid":false,"given":"Gayatri","family":"Devi","sequence":"additional","affiliation":[{"name":"Park Avenue Neurology, New York, NY, USA"},{"name":"Departments of Neurology and Psychiatry, Zucker School of Medicine, Hempstead, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00838-z"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.4161"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.30"},{"key":"e_1_3_3_6_2","volume-title":"Evaluation of slower titration of donanemab and its impact on ARIA incidence: results from a Phase 3 extension cohort (TRAILBLAZER-ALZ 2). PosterCTAD 2023, Boston, MA.","author":"Mintun M","unstructured":"Mintun M, Sims J, et al. Evaluation of slower titration of donanemab and its impact on ARIA incidence: results from a Phase 3 extension cohort (TRAILBLAZER-ALZ 2). Poster. In: CTAD 2023, Boston, MA., 2023."},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-023-00633-2"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature19323"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-019-0281-2"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.18059"},{"key":"e_1_3_3_11_2","volume-title":"Continued risk of ARIA after switching amyloid-targeting monoclonal antibodies in Alzheimer\u2019s disease: results from the ICEBERG 2024 trialCTAD 2024","unstructured":"Continued risk of ARIA after switching amyloid-targeting monoclonal antibodies in Alzheimer\u2019s disease: results from the ICEBERG 2024 trial. In: CTAD 2024, 2024."}],"container-title":["Journal of Alzheimer\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13872877251366657","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/13872877251366657","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/13872877251366657","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:11:34Z","timestamp":1777371094000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/13872877251366657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1177\/13872877251366657"],"URL":"https:\/\/doi.org\/10.1177\/13872877251366657","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,13]]}}}